Distinctive localization of antigen-presenting cells in human lymph nodes
Distinctive localization of antigen-presenting cells in human lymph nodes
复制标题
DOI：
10.1182/blood-2008-06-165266
复制
发表时间：
2009-02-05
期刊：
影响因子：
20.3
通讯作者：
Dunbar, P. Rod
中科院分区：
文献类型：
--
作者：
Angel, Catherine E.;Chen, Chun-Jen J.;Dunbar, P. Rod
专业抗原呈递细胞（APCs）是免疫系统的前哨细胞，它向T淋巴细胞呈递抗原并介导适当的免疫反应。因此，令人惊讶的是，人类淋巴结中专业apc的知识有限。利用三色免疫组织化学技术，我们在人类淋巴结中发现了不包括浆细胞样apc的apc，它们分为两类不重叠的apc:(1) CD209(+) apc，共表达CD206、CD14和CD68的组合，占据髓系，排列在被囊和小梁上，也散布在皮层旁弥漫性t淋巴细胞区；(2)表达CD1a、CD207和CD208组合的apc，它们总是局限于副皮层。令人惊讶的是，这第二类apc在许多淋巴结中几乎完全缺失。我们的数据表明，大多数CD208（+）细胞，通常被称为“间指细胞”，来自迁移的APC，并且一直居住在人类淋巴结旁皮层的主要APC亚群是CD209（+）亚群。所有APC亚群都被证明与纤维网状网络密切接触。在人淋巴结旁皮层中鉴定2种不同的APC群体对理解t淋巴细胞反应和优化疫苗设计具有重要意义。（血液杂志，2009;113:1257-1267）
Professional antigen-presenting cells (APCs) are sentinel cells of the immune system that present antigen to T lymphocytes and mediate an appropriate immune response. It is therefore surprising that knowledge of the professional APCs in human lymph nodes is limited. Using 3-color immunohistochemistry, we have identified APCs in human lymph nodes, excluding plasmacytoid APCs, that fall into 2 nonoverlapping classes: (1) CD209(+) APCs, coexpressing combinations of CD206, CD14, and CD68, that occupied the medullary cords, lined the capsule and trabeculae and were also scattered throughout the diffuse T-lymphocyte areas of the paracortex; and (2) APCs expressing combinations of CD1a, CD207, and CD208, that were always restricted to the paracortex. Surprisingly, this second class of APCs was almost entirely absent from many lymph nodes. Our data suggest that most CD208(+) cells, often referred to as "interdigitating cells," derive from migratory APCs, and that the major APC subset consistently resident in the paracortex of human lymph nodes is the CD209(+) subset. All APC subsets were demonstrated to be in close contact with the fibroreticular network. The identification of 2 distinct APC populations in the paracortex of human lymph nodes has important implications for understanding T-lymphocyte responses and optimizing vaccine design. (Blood. 2009; 113: 1257-1267)